Opentrons, a NYC-based lab automation company, closed a $10M seed funding.
The round was led by Khosla Ventures with participation from Lerer Hippeau Ventures, Y Combinator Continuity Fund, and Jeff Kindler, former CEO of Pfizer.
The company is using the funds to develop and launch its newest lab robot, OT-2 and new no-code Protocol Designer, expand operations and grow customer adoption.
Led by Chiu Chau, Co-Founder and CEO, Will Canine, Co-founder and Chief Product Officer, Opentrons provides biologists with hardware, an open software platform and pipetting robots to automate manual lab work and empower collaborative research for life scientists. The company’s solutions are used by scientists at 70% of top 10 largest pharma companies and 90% of top 50 biology research universities.
Opentrons’ newest robot, OT-2, allows biologists to run an experiment quickly. OT-2 includes access to a library of verified protocols developed by hundreds of scientists from across the scientific community. Key OT-2 features include:
– Protocol Designer, an intuitive, visual design program, allows biologists to create and customize protocols for OT-2 without writing code
– Modular additions like temperature and magnet decks that allow users to increase OT-2’s functionality
– Novel “tip probe” auto-calibration assistance and electronic pipettes
– Access to a library of more than 100 verified protocols and 40 scientific community-developed projects to enable better reproducibility across the scientific community
– Open API for integration with tools like Amazon Alexa, microscopes, and computer vision.